+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • ID: 5553772
  • Report
  • February 2022
  • Region: Global
  • 44 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Amgen Inc
  • Incyte Corp
  • Novartis AG
  • Sanofi
  • Yakult Honsha Co Ltd
  • Zovis Pharmaceuticals
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

According to the recently published report 'Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Serine/threonine-protein kinase Pim-2 is an enzyme encoded by the PIM2. It is involved in cell survival and cell proliferation. It regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. It mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade.

The report 'SerineThreonine Protein Kinase Pim 2 - Drugs In Development, 2022' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 2 respectively. Report covers products from therapy areas Oncology which include indications Hematological Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelofibrosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Diffuse Large B-Cell Lymphoma, Liver Cancer, Lung Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myeloproliferative Disorders, Non-Small Cell Lung Carcinoma, Pancreatic Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor and Triple-Negative Breast Cancer (TNBC).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)
  • The report reviews Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc
  • Incyte Corp
  • Novartis AG
  • Sanofi
  • Yakult Honsha Co Ltd
  • Zovis Pharmaceuticals

IntroductionReport CoverageOverview
Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies

Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Companies Involved in Therapeutics Development
  • Amgen Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • NewBay Medical Technology Co Ltd
  • Novartis AG
  • Sanofi
  • Sumitomo Dainippon Pharma Oncology, Inc
  • Yakult Honsha Co Ltd
  • Zovis Pharmaceuticals

Drug Profiles
  • GDC-0570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • IBL-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • INCB-53914 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • JP-11646 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • LGB-321 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule to Inhibit PIM1 and PIM2 for Hematological Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules to Inhibit PIM1 and PIM2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit PIM2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • TP-3654 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events

Dormant ProductsDiscontinued ProductsProduct Development Milestones
Featured News & Press Releases
  • Apr 10, 2021: Sumitomo Dainippon Pharma Oncology presents on TP-3654 at AACR Virtual Annual Meeting I 2021
  • May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigational agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020
  • Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with myelofibrosis
  • May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with advanced solid tumors
  • Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer
  • Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology
  • Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma
  • Apr 04, 2014: Roswell Park to Present Findings on Jasco Pharmaceuticals’ Novel PIM Inhibitor at AACR 2014

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Analyst
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Indications, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Pipeline by Amgen Inc, 2022
  • Pipeline by Incyte Corp, 2022
  • Pipeline by Inflection Biosciences Ltd, 2022
  • Pipeline by NewBay Medical Technology Co Ltd, 2022
  • Pipeline by Novartis AG, 2022
  • Pipeline by Sanofi, 2022
  • Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022
  • Pipeline by Yakult Honsha Co Ltd, 2022
  • Pipeline by Zovis Pharmaceuticals, 2022
  • Dormant Products, 2022
  • Discontinued Products, 2022

List of Figures
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Top 10 Indications, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Amgen Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • NewBay Medical Technology Co Ltd
  • Novartis AG
  • Sanofi
  • Sumitomo Dainippon Pharma Oncology, Inc
  • Yakult Honsha Co Ltd
  • Zovis Pharmaceuticals
Note: Product cover images may vary from those shown